CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, Imatinib-treated CML patients in complete molecular remission (CMR) displayed a selective depletion of effector Tregs which was accompanied by an increase in effector/memory CD8+ CTLs in contrast to CMR patients who did not reach a complete molecular remission (80).